Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol.
Vivash L, Johns H, Churilov L, MacPhail S, Casillas-Espinosa P, Malpas C, Shultz SR, Tailby C, Wijayath M, Reutens D, Gillinder L, Perucca P, Carney P, Nicolo JP, Lawn N, Kwan P, Velakoulis D, Hovens CM, O'Brien TJ.
Vivash L, et al. Among authors: reutens d.
BMJ Open. 2023 Oct 27;13(10):e075888. doi: 10.1136/bmjopen-2023-075888.
BMJ Open. 2023.
PMID: 37890967
Free PMC article.